{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:41:58Z","timestamp":1793036518040,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biologicals.2026.101918","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:31:16Z","timestamp":1791624676000},"page":"101918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sterility testing in the era of decentralised cell therapy: Challenges, innovations, and future directions"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2127-832X","authenticated-orcid":false,"given":"Athena","family":"Stathoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9558-395X","authenticated-orcid":false,"given":"Dominic","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Doig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Fiorenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2026.101918_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101918_bib2","series-title":"<71> sterility tests [Internet]. Rockville, MD: united States pharmacopeial convention","year":"2022"},{"key":"10.1016\/j.biologicals.2026.101918_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2026.101918_bib4","article-title":"Sterility testing of cell therapy products \u2014 have we moved forward in the last 20 years?","volume":"59","author":"Lys\u00e1k","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.biologicals.2026.101918_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcyt.2020.08.007","article-title":"Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation","volume":"23","author":"Lam","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biologicals.2026.101918_bib6","series-title":"Pharmaceutical technology\/pharmaceutical technology Europe trends in manufacturing eBook","first-page":"4","article-title":"Rapid sterility methods for CAR T-cell therapies","author":"Dol\u00e1kov\u00e1","year":"2024"},{"key":"10.1016\/j.biologicals.2026.101918_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12247-017-9303-z","article-title":"Performance survey and comparison between rapid sterility testing method and pharmacopoeia sterility test","volume":"13","author":"Bugno","year":"2018","journal-title":"J Pharm Innov"},{"key":"10.1016\/j.biologicals.2026.101918_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01492-19","article-title":"Sterility testing for cellular therapies: what is the role of the clinical microbiology laboratory?","volume":"58","author":"Gebo","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.biologicals.2026.101918_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01548-18","article-title":"Comprehensive evaluation of compendial USP, BacT\/Alert Dual-T, and Bactec FX for detection of product sterility testing contaminants","volume":"57","author":"England","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.biologicals.2026.101918_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10561-014-9474-5","article-title":"A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing","volume":"16","author":"Klarmann","year":"2015","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.biologicals.2026.101918_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcyt.2017.11.009","article-title":"Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: best practices and clinical significance","volume":"20","author":"Golay","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biologicals.2026.101918_bib12","series-title":"<1223> validation of alternative microbiological methods [Internet]. Rockville, MD: united States pharmacopeial convention","year":"2015"},{"key":"10.1016\/j.biologicals.2026.101918_bib13","series-title":"U.S. department of health and human services, food and drug administration","article-title":"Considerations for the development of Chimeric Antigen Receptor (CAR) T cell products: guidance for industry [Internet]","year":"2024"},{"key":"10.1016\/j.biologicals.2026.101918_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01350-23","article-title":"Machine learning-based detection of adventitious microbes in T-cell therapy cultures using long-read sequencing","volume":"11","author":"Strutt","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.biologicals.2026.101918_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jcyt.2012.09.006","article-title":"Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs","volume":"15","author":"Abou-El-Enein","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biologicals.2026.101918_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.biologicals.2026.101918_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transp"},{"key":"10.1016\/j.biologicals.2026.101918_bib18","article-title":"Industrializing CAR-T cell therapy: impact of automation on cost and space efficiency of manufacturing facilities","volume":"13","author":"Weltin","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.biologicals.2026.101918_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.biologicals.2026.101918_bib20","article-title":"GMP manufacturing of cell and gene therapy products: challenges, opportunities, and pathways forward","author":"Bauer","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.biologicals.2026.101918_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1591751","article-title":"Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products: technical and regulatory considerations","volume":"12","author":"von der Leyen","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.biologicals.2026.101918_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2025.200977","article-title":"Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial","author":"Palani","year":"2025","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.biologicals.2026.101918_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5741.5741","article-title":"Microbial contamination of haematopoietic stem cell products: a single centre experience","volume":"128","author":"Avenoso","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biologicals.2026.101918_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.biologicals.2026.101918_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2018.08.003","article-title":"Prospective evaluation of a practical guideline for managing positive sterility test results in cell therapy products","volume":"25","author":"Panch","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.biologicals.2026.101918_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12866-021-02391-z","article-title":"ddPCR allows 16S rRNA gene amplicon sequencing of very small DNA amounts from low-biomass samples","volume":"21","author":"Abellan-Schneyder","year":"2021","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.biologicals.2026.101918_bib27","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41467-020-16224-6","article-title":"A quantitative sequencing framework for absolute abundance measurements of mucosal and lumenal microbial communities","volume":"11","author":"Barlow","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.biologicals.2026.101918_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2024.112147","article-title":"Development of a multiplex PCR assay and quantification of microbial markers by ddPCR for identification of saliva and vaginal fluid","volume":"362","author":"Dass","year":"2024","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.biologicals.2026.101918_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00338-23","article-title":"Direct 16S\/18S rRNA gene PCR followed by Sanger sequencing as a clinical diagnostic tool for detection of bacterial and fungal infections: a systematic review and meta-analysis","volume":"61","author":"Drevinek","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.biologicals.2026.101918_bib30","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181170","article-title":"Application of droplet digital PCR to detect the pathogens of infectious diseases","volume":"38","author":"Li","year":"2018","journal-title":"Biosci Rep"},{"key":"10.1016\/j.biologicals.2026.101918_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202500253","article-title":"Rapid universal detection of high-risk and low-abundance microbial contaminations in CAR-T cell therapy","volume":"9","author":"Wu","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.biologicals.2026.101918_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2478\/ahp-2020-0007","article-title":"Microbial contamination risk in hematopoietic stem cell products: retrospective analysis of 1996\u20132016 data","volume":"51","author":"Antoniewicz-Papis","year":"2020","journal-title":"Acta Haematol Pol"},{"key":"10.1016\/j.biologicals.2026.101918_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1574-6976.2009.00200.x","article-title":"Recent findings on the viable but nonculturable state in pathogenic bacteria","volume":"34","author":"Oliver","year":"2010","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.biologicals.2026.101918_bib34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.5731\/pdajpst.2022.012775","article-title":"A rapid sterility method using solid phase cytometry for cell-based preparations and culture media and buffers","volume":"77","author":"Mohammadi","year":"2023","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.biologicals.2026.101918_bib36","series-title":"Recommendation paper: strategic framework to address future harmonisation needs for cell and gene therapy products [Internet]","year":"2025"},{"key":"10.1016\/j.biologicals.2026.101918_bib37","first-page":"121","article-title":"Regulation (EC) no 1394\/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001\/83\/EC and regulation (EC) no 726\/2004","year":"2007","journal-title":"Off J Eur Union"},{"key":"10.1016\/j.biologicals.2026.101918_bib38","article-title":"ATMPs prepared under hospital exemption: European blood alliance position paper","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.biologicals.2026.101918_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.biologicals.2026.101918_bib41","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jval.2022.02.007","article-title":"Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-cell lymphoma","volume":"25","author":"Chen","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.biologicals.2026.101918_bib42","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/vaccines12121348","article-title":"Rapidly manufactured CAR-T with conserved cell stemness and distinctive cytokine-secreting profile shows improved anti-tumor efficacy","volume":"12","author":"Tsao","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biologicals.2026.101918_bib43","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3390\/cells10071797","article-title":"Development and validation of a good manufacturing process for IL-4-driven expansion of chimeric cytokine receptor-expressing CAR T-cells","volume":"10","author":"van Schalkwyk","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biologicals.2026.101918_bib44","article-title":"Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: experiences of an academic in Thailand","volume":"32","author":"Luanpitpong","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.biologicals.2026.101918_bib45","article-title":"Decentralized point-of-care manufacturing of CD19 chimeric antigen receptor T cells in Mexico","volume":"11","author":"Salazar-Riojas","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.biologicals.2026.101918_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.03.428","article-title":"Set-up of an in-house GMP-compliant production in an Austrian University clinic - a pre-requisite for innovative CAR-T cell therapies","volume":"27","author":"Wagner","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biologicals.2026.101918_bib47","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/bloodadvances.2023012240","article-title":"\u201cDon't keep me waiting\u201d: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes","volume":"8","author":"Vadgama","year":"2024","journal-title":"Blood Adv"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105626000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105626000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:07:27Z","timestamp":1793034447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105626000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"alternative-id":["S1045105626000461"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2026.101918","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sterility testing in the era of decentralised cell therapy: Challenges, innovations, and future directions","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2026.101918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}],"article-number":"101918"}}